Status:
ACTIVE_NOT_RECRUITING
Endocrine Disrupting Chemical Exposure and Testicular Cancer
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Testicular Cancer
Eligibility:
MALE
15-50 years
Brief Summary
DISRUPT is a Danish nested case-control study that is currently being conducted to explore the impact of prenatal exposure to endocrine disrupting chemicals on testicular cancer risk (including histol...
Detailed Description
Objectives and background Hypothesis: The central hypothesis is that testicular cancer has a fetal origin and that exposure to Endocrine Disrupting Chemicals (EDCs) plays a pivotal role in the program...
Eligibility Criteria
Inclusion
- Male
- Available stored maternal serum and/or maternal amniotic fluid
Exclusion
- other cancer
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04848545
Start Date
June 1 2020
End Date
December 31 2030
Last Update
April 21 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Growth and Reproduction, Rigshospitalet
Copenhagen, Denmark, 2100
2
EDMaRC, Rigshospitalet secton 5064
Copenhagen, Denmark, 2100